Alkermes (ALKS)

Add to Watchlists
Create an Alert
44.82 +0.69  +1.58% NASDAQ Apr 21, 11:35AM BATS Real time Currency in USD
View Full Chart
ALKS Price Chart
View All Events

ALKS Events

Date Type Description
Feb 27 Misc Q4 2013 Alkermes Conference Call
Feb 27 Earnings Q4 2013 Alkermes Earnings Results. Estimate: 0.08.
Oct 31 Misc Alkermes PLC Q3 2013 Conference Call
Oct 31 Earnings Alkermes PLC Reports Financial Results for Quarter Ended Sept. 30, 2013. Estimate: 0.13.
Jul 25 Misc Alkermes PLC Quarter Ended June 30, 2013 Earnings Conference Call
Jul 25 Misc Alkermes PLC Quarter Ended September 30, 2013 Earnings Conference Call
Jul 25 Earnings Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended June 30, 2013. Estimate: 0.16.
Jul 25 Earnings Alkermes to Host Conference Call to Discuss Financial Results for Quarter Ended Sept. 30, 2013. Estimate: 0.16.
Jul 17 Misc Alkermes Announces Webcast of R&d Day on July 17, 2013
May 23 Earnings Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2013. Estimate: 0.15.
View All Performance Charts

ALKS Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Alkermes is up 50.79% over the last year vs S&P 500 Total Return up 23.77%, Alexion Pharmaceuticals up 57.22%, and Amgen up 8.32%.

Get Quote for

PDF Report for ALKS

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download ALKS Pro Report PDF
Advertisement

Portfolio Strategies Featuring ALKS

Did Alkermes make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

ALKS Profile

  • Sector: Healthcare
  • Industry: Biotechnology
  • Headquarters Country: Ireland
  • Headquarters State/Province: N/A
  • Incorporation Country: Ireland
  • Incorporation State/Province: N/A
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: March 31, 2015
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The company is the result of a merger in September 2011 between Alkermes, Inc. and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Elan Corporation, plc. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. The company was founded in 1987.

Recent Quotes

Symbol Price Chg Chg % Market Cap
ALKS 44.82 +0.69 +1.58% 6.447B
Create Watchlist from Quotes
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.